Maria Fardis's most recent trade in Obsidian Therapeutics Inc. was a trade of 37,653 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Aug. 3, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Obsidian Therapeutics Inc | Dr. Maria Fardis, PhD | Director | 03 Aug 2026 | 37,653 | 37,653 | - | - | Stock Option (Right to Buy) | ||
| CRISPR Therapeutics AG | Dr. Maria Fardis, PhD | Director | 05 Jun 2026 | 13,000 | 13,000 | - | - | Stock Option (Right to Buy) | ||
| CRISPR Therapeutics AG | Dr. Maria Fardis, PhD | Director | 05 Jun 2025 | 13,000 | 13,000 | - | - | Stock Option (Right to Buy) | ||
| CRISPR Therapeutics AG | Dr. Maria Fardis, PhD | Director | 30 May 2024 | 13,000 | 13,000 | - | - | Stock Option (Right to Buy) | ||
| CRISPR Therapeutics AG | Dr. Maria Fardis, PhD | Director | 09 Jun 2022 | 24,000 | 24,000 | - | - | Stock Option (Right to Buy) |